When was Immutep founded?

Immutep was founded in 2001 and raised its 1st funding round 17 years after it was founded.

Where is Immutep located?

Immutep is headquartered in Sydney, Australia.

How many employees does Immutep have?

As of May 31, 2026, the latest employee count at Immutep is 56.

Is Immutep a funded company?

Immutep is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Mar 11, 2018.

When was the latest funding round of Immutep?

Immutep's latest funding was a $***** Post IPO round on Jun 21, 2021, with participation from 0 investor.

Where does Immutep rank among its competitors?

Immutep ranks 464th amongst 3489 active competitors, of which 1190 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Immutep?

Immutep's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Immutep - 2026 Company Profile, Team, Funding & Competitors

Q: Is Immutep an acquired company?

Immutep got acquired by Prima Biomed on Oct 02, 2014.

Immutep is an acquired company based in Sydney (Australia), founded in 2001. It operates as a Developer of immunotherapies for the treatment of cancer and autoimmune diseases. Immutep has raised an undisclosed amount in funding. The company has 3489 active competitors, including 1190 funded and 817 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company's product line include Eftilagimod alpha for metastatic cancers, IMP761, a humanized IgG4 monoclonal antibody for immunological diseases, and LAG525 for autoimmune diseases.

Website: www.immutep.com/
Social
Email ID: *****@immutep.com
Phone Number: +61 **********
Part Of

Key Metrics

Founded Year

2001

Location

Sydney, Australia

Stage

Acquired

Latest Funding Round

Post IPO, Jun 21, 2021, $*****

Investors

Ridgeback Capital Management & 5 more

Ranked

464^th among 3489 active competitors

Employee Count

56 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3309 more

Exit Details

Acquired by Prima Biomed (Oct 02, 2014)

View Immutep's full profile

Immutep got acquired by Prima Biomed on Oct 02, 2014 at an acquisition amount of $*****.

Click here to take a look at Immutep's acquisition in detail

Immutep has raised funding over 7 rounds. Its first funding round was on Mar 11, 2018. Immutep has 6 institutional investors.

Here is the list of recent funding rounds of Immutep:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 21, 2021	3755529	Post IPO	3653154	4927102	3293096	3557721
Aug 31, 2020	7934826	Grant (prize money)	4332676	5547687	4878361	ARC
Sep 23, 2019	1473521	Post IPO	8795584	9767080	7894197	GSK

Access funding benchmarks and valuations. Sign up today!

View details of Immutep's funding rounds and investors

Immutep's employee count trend

Immutep has 56 employees as of May 26. Here is Immutep's employee count trend over the years:

Uncover Immutep's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immutep include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Immutep, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
464th	Immutep 2001, Sydney (Australia), Acquired	Developer of immunotherapies for the treatment of cancer and autoimmune diseases	-	Ridgeback Capital Management, ARC & 4 others	54/100